Findings

What do systematic reviews say?

89 questions · 92 findings · 23 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 27 · 29.3%GRADE not reported 14 · 15.2%Very low 7 · 7.6%Low 17 · 18.5%Moderate 23 · 25%High 4 · 4.3%

Acetyl‐L‐carnitine vs methylcobalamin

Adverse events · the treatment of diabetic peripheral neuropathy

Acetyl‐L‐carnitine showed no clear difference in adverse events compared with methylcobalamin (low certainty).

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
RR 1.01 [0.68, 1.52]
1 study · 232 participants
Low

Acetyl‐L‐carnitine vs methylcobalamin

Pain at 6 months or more · the treatment of diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acetyl‐L‐carnitine vs methylcobalamin

Functional impairment and disability Assessed by change in NDS score (range of possible scores from 0 (normal function) to 10 (maximal disability) · the treatment of diabetic peripheral neuropathy

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 232 participants
Low

Acetyl‐L‐carnitine vs methylcobalamin

Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events in glycogen storage disease type V · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 28 participants
GRADE not reported

Intervention not reported

Maximum voluntary contraction in mitochondrial diseases % · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 38 participants
High

Intervention not reported

Maximum voluntary contraction in glycogen storage disease type V % · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
High

Intervention not reported

Impairment of activities of daily living (ADL) in glycogen storage disease type V Visual numeric scale. Scale from: 1 to 10. · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
High

Intervention not reported

Adverse events in mitochondrial diseases · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 38 participants
GRADE not reported